Trials / Completed
CompletedNCT03502616
Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 270 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if tofacitinib is safe and effective in subjects with active ankylosing spondylitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tofacitinib | Oral administration twice per day |
Timeline
- Start date
- 2018-06-07
- Primary completion
- 2019-12-19
- Completion
- 2020-08-20
- First posted
- 2018-04-18
- Last updated
- 2021-09-17
- Results posted
- 2021-01-11
Locations
99 sites across 14 countries: United States, Australia, Bulgaria, Canada, China, Czechia, France, Hungary, Israel, Poland, Russia, South Korea, Turkey (Türkiye), Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03502616. Inclusion in this directory is not an endorsement.